No Data
There's Reason For Concern Over Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Price
Zhejiang Hisoar Pharmaceutical (002099.SZ): plans to repurchase company shares worth 0.15 billion to -0.3 billion yuan.
On April 9, Gelonghui reported that Zhejiang Hisoar Pharmaceutical (002099.SZ) announced that the company will use its own/or raised funds to repurchase shares through a centralized bidding method. The total amount for this repurchase will not be less than RMB 0.15 billion (including this amount) and will not exceed RMB 0.3 billion (including this amount). The repurchase price will not exceed 7.46 yuan per share (including this amount). If calculated based on the upper limit of the total repurchase amount of RMB 300 million and the upper limit of the repurchase share price of 7.46 yuan per share, the estimated number of repurchased shares will be approximately 40.21 million shares, accounting for about 2.48% of the company's total share capital at present. The specific repurchase amount and repurchased quantity will be based on the repurchase.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Zhejiang Hisoar Pharmaceutical (SZSE:002099) Shareholders Are up 6.6% This Past Week, but Still in the Red Over the Last Three Years
Hisoar Pharmaceutical's Diquafosol Sodium Gets Nod to Enter South Korean Market
Zhejiang Hisoar Pharmaceutical (002099.SZ): Diquafosol Sodium Active Pharmaceutical Ingredient has obtained the South Korea Active Pharmaceutical Ingredient Pharmaceutical registration certificate.
On February 6, Gelonghui reported that Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) announced that it has recently received the Active Pharmaceutical Ingredient registration certificate from the South Korean Food and Drug Administration (South Korea MFDS). Difluprednate is a P2Y2 receptor agonist, and its eye drop formulation is used for the treatment of dry eye disease. Difluprednate acts on the P2Y2 receptors of conjunctival epithelial and goblet cell membranes, upregulating intracellular calcium ion concentrations to promote the secretion of water and mucus, thereby improving the symptoms of dry eye disease. According to data from Minnei Network, difluprednate eye drops are expected to be available in public hospitals in urban China in 2023.
Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE:002099) Shares May Have Slumped 32% But Getting In Cheap Is Still Unlikely
